Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
Abstract Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-01-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1007/s40744-018-0137-z |
| _version_ | 1818268436768227328 |
|---|---|
| author | Prashanth Sunkureddi Dominick Latremouille-Viau Mark K. Meiselbach Jipan Xie Peter Hur Reeti Joshi |
| author_facet | Prashanth Sunkureddi Dominick Latremouille-Viau Mark K. Meiselbach Jipan Xie Peter Hur Reeti Joshi |
| author_sort | Prashanth Sunkureddi |
| collection | DOAJ |
| description | Abstract Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with PsA in real-world settings. This US medical chart review describes clinical and treatment characteristics of patients with psoriatic arthritis (PsA) who were prescribed secukinumab and rheumatologist-reported reasons for prescribing secukinumab in clinical practice. Methods This US medical chart review included patients with physician-diagnosed PsA aged ≥ 18 years initiating secukinumab after January 15, 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, comorbidity profiles, and treatment histories before or on the date of the first secukinumab prescription recorded in the medical chart. Information on reasons for secukinumab prescription and dosing was also collected. Results Medical charts from 153 patients with PsA who initiated secukinumab were reviewed by 46 rheumatologists between July 7, 2017, and August 11, 2017. Overall, 53.6% of patients were male, mean (standard deviation) age was 47.3 (11.5) years, and 24.8% were biologic naive. The most common reasons for secukinumab prescription among biologic-naive and biologic-experienced patients, respectively, were efficacy/effectiveness of secukinumab (84.2%) and failure of other prior biologics (80.9%). Nearly all patients (94.1%) received a loading regimen, including 150 mg every week (32.7%) and 300 mg every week (61.4%). Overall, 145 patients (94.8%) received ≥ 1 maintenance dose, of whom 49.7% received 150 mg every 4 weeks and 50.3% received 300 mg every 4 weeks. Conclusions At the time of the chart review, most patients with PsA who initiated secukinumab were biologic experienced, although one-quarter received secukinumab as first-line biologic therapy. Efficacy/effectiveness of secukinumab and failure of other biologics were the most common reasons for initiating secukinumab. Funding Novartis Pharmaceuticals Corporation, East Hanover, NJ. Plain Language Summary Plain language summary available for this article. |
| first_indexed | 2024-12-12T20:38:28Z |
| format | Article |
| id | doaj.art-a79c8d4d9b9846c5b5418b3ca3095672 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-12-12T20:38:28Z |
| publishDate | 2019-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-a79c8d4d9b9846c5b5418b3ca30956722022-12-22T00:12:50ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842019-01-01618910010.1007/s40744-018-0137-zCharacteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart ReviewPrashanth Sunkureddi0Dominick Latremouille-Viau1Mark K. Meiselbach2Jipan Xie3Peter Hur4Reeti Joshi5The University of Texas Medical Branch at GalvestonAnalysis Group, IncAnalysis Group, IncAnalysis Group, IncNovartis Pharmaceuticals CorporationBaylor College of MedicineAbstract Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with PsA in real-world settings. This US medical chart review describes clinical and treatment characteristics of patients with psoriatic arthritis (PsA) who were prescribed secukinumab and rheumatologist-reported reasons for prescribing secukinumab in clinical practice. Methods This US medical chart review included patients with physician-diagnosed PsA aged ≥ 18 years initiating secukinumab after January 15, 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, comorbidity profiles, and treatment histories before or on the date of the first secukinumab prescription recorded in the medical chart. Information on reasons for secukinumab prescription and dosing was also collected. Results Medical charts from 153 patients with PsA who initiated secukinumab were reviewed by 46 rheumatologists between July 7, 2017, and August 11, 2017. Overall, 53.6% of patients were male, mean (standard deviation) age was 47.3 (11.5) years, and 24.8% were biologic naive. The most common reasons for secukinumab prescription among biologic-naive and biologic-experienced patients, respectively, were efficacy/effectiveness of secukinumab (84.2%) and failure of other prior biologics (80.9%). Nearly all patients (94.1%) received a loading regimen, including 150 mg every week (32.7%) and 300 mg every week (61.4%). Overall, 145 patients (94.8%) received ≥ 1 maintenance dose, of whom 49.7% received 150 mg every 4 weeks and 50.3% received 300 mg every 4 weeks. Conclusions At the time of the chart review, most patients with PsA who initiated secukinumab were biologic experienced, although one-quarter received secukinumab as first-line biologic therapy. Efficacy/effectiveness of secukinumab and failure of other biologics were the most common reasons for initiating secukinumab. Funding Novartis Pharmaceuticals Corporation, East Hanover, NJ. Plain Language Summary Plain language summary available for this article.http://link.springer.com/article/10.1007/s40744-018-0137-zBiologicalsEpidemiologyPsoriatic arthritisSpondylarthropathies |
| spellingShingle | Prashanth Sunkureddi Dominick Latremouille-Viau Mark K. Meiselbach Jipan Xie Peter Hur Reeti Joshi Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review Rheumatology and Therapy Biologicals Epidemiology Psoriatic arthritis Spondylarthropathies |
| title | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| title_full | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| title_fullStr | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| title_full_unstemmed | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| title_short | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| title_sort | characteristics of patients with psoriatic arthritis receiving secukinumab and reasons for initiation a us retrospective medical chart review |
| topic | Biologicals Epidemiology Psoriatic arthritis Spondylarthropathies |
| url | http://link.springer.com/article/10.1007/s40744-018-0137-z |
| work_keys_str_mv | AT prashanthsunkureddi characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview AT dominicklatremouilleviau characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview AT markkmeiselbach characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview AT jipanxie characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview AT peterhur characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview AT reetijoshi characteristicsofpatientswithpsoriaticarthritisreceivingsecukinumabandreasonsforinitiationausretrospectivemedicalchartreview |